MY139336A - N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors - Google Patents

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Info

Publication number
MY139336A
MY139336A MYPI20033320A MYPI20033320A MY139336A MY 139336 A MY139336 A MY 139336A MY PI20033320 A MYPI20033320 A MY PI20033320A MY PI20033320 A MYPI20033320 A MY PI20033320A MY 139336 A MY139336 A MY 139336A
Authority
MY
Malaysia
Prior art keywords
compounds
cyclin dependent
pyrazolopyrimidines
heteroaryl
kinase inhibitors
Prior art date
Application number
MYPI20033320A
Other languages
English (en)
Inventor
Timothy J Guzi
Park Haengsoon
Paruch Kamil
Michael P Dwyer
Ronald J Doll
Girijavallabhan Viyyoor Moopil
Lawrence W Dillard
Vinh D Tran
He Zhen Min
James Ray Anthony
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of MY139336A publication Critical patent/MY139336A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20033320A 2002-09-04 2003-09-03 N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors MY139336A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40803002P 2002-09-04 2002-09-04

Publications (1)

Publication Number Publication Date
MY139336A true MY139336A (en) 2009-09-30

Family

ID=31978549

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20033320A MY139336A (en) 2002-09-04 2003-09-03 N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Country Status (17)

Country Link
US (2) US7078525B2 (enExample)
EP (1) EP1534709B1 (enExample)
JP (2) JP2006501260A (enExample)
KR (1) KR20050058507A (enExample)
CN (1) CN1310918C (enExample)
AR (1) AR041134A1 (enExample)
AT (1) ATE364608T1 (enExample)
CA (1) CA2497444C (enExample)
DE (1) DE60314427T2 (enExample)
ES (1) ES2285164T3 (enExample)
MX (1) MXPA05002573A (enExample)
MY (1) MY139336A (enExample)
NZ (1) NZ539162A (enExample)
PE (1) PE20041076A1 (enExample)
TW (1) TW200413377A (enExample)
WO (1) WO2004022559A1 (enExample)
ZA (1) ZA200501851B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7067661B2 (en) * 2002-09-04 2006-06-27 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003263071B2 (en) * 2002-09-04 2007-03-15 Merck Sharp & Dohme Llc Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
BRPI0407834A (pt) 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
EP1666468A4 (en) * 2003-09-09 2007-03-21 Ono Pharmaceutical Co CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
CN101300233A (zh) 2005-09-09 2008-11-05 先灵公司 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
TWI333953B (en) * 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0704652D0 (en) * 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
EP2155725A1 (en) * 2007-06-07 2010-02-24 Schering Corporation Synthesis of substituted-3-aminopyrazoles
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
WO2014066795A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
EP2970307B1 (en) * 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
AU2015277212B2 (en) 2014-06-17 2020-07-02 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
PL3164130T3 (pl) 2014-07-01 2020-02-28 Millennium Pharmaceuticals, Inc. Związki heteroarylowe użyteczne jako inhibitory enzymu aktywującego sumo
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
WO2017015425A1 (en) * 2015-07-23 2017-01-26 Bristol-Myers Squibb Company Tgf beta receptor antagonists
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
EP3377908B1 (en) 2015-11-18 2020-08-05 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
AU2018256459B2 (en) * 2017-04-21 2023-12-07 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
WO1992018504A1 (en) * 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
PT714898E (pt) * 1994-06-21 2002-04-29 Otsuka Pharma Co Ltd Derivado de pirazolo¬1,5-a|pirimidina
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
FR2805160B1 (fr) 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
US6282096B1 (en) * 2000-04-28 2001-08-28 Siliconware Precision Industries Co., Ltd. Integration of heat conducting apparatus and chip carrier in IC package
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (fr) 2000-12-04 2003-04-18 Oreal Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
JP4733794B2 (ja) * 2000-12-26 2011-07-27 共栄電工株式会社 部材内面の表面処理方法および装置
US6919815B2 (en) * 2002-01-24 2005-07-19 Emerson Electric Co. Appliance control communication methods and apparatus
WO2003091256A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003263071B2 (en) * 2002-09-04 2007-03-15 Merck Sharp & Dohme Llc Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine

Also Published As

Publication number Publication date
CA2497444C (en) 2010-11-30
ZA200501851B (en) 2005-09-08
US7078525B2 (en) 2006-07-18
KR20050058507A (ko) 2005-06-16
EP1534709A1 (en) 2005-06-01
AR041134A1 (es) 2005-05-04
US20040102451A1 (en) 2004-05-27
US20060235025A1 (en) 2006-10-19
CN1738821A (zh) 2006-02-22
NZ539162A (en) 2006-07-28
US7470695B2 (en) 2008-12-30
CN1310918C (zh) 2007-04-18
CA2497444A1 (en) 2004-03-18
DE60314427D1 (de) 2007-07-26
JP2006501260A (ja) 2006-01-12
ATE364608T1 (de) 2007-07-15
AU2003268357A1 (en) 2004-03-29
PE20041076A1 (es) 2005-01-22
MXPA05002573A (es) 2005-09-08
EP1534709B1 (en) 2007-06-13
JP2010132704A (ja) 2010-06-17
HK1071570A1 (en) 2005-07-22
DE60314427T2 (de) 2008-06-12
TW200413377A (en) 2004-08-01
ES2285164T3 (es) 2007-11-16
WO2004022559A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137888A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO2007044449A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
DE602006014848D1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhän
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
WO2007032936A3 (en) Azafused cyclin dependent kinase inhibitors
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
WO2003063764A3 (en) 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
TH148526B (th) ไพราโซโลไพริมิดีนชนิดใหม่ (Novel pyrazolopyrimidines) ล่าสุดในฐานะตัวยับยั้งไซคลินดีเพนเดนท์คิเนส (Cyclin dependent kinase inhibitors)